Filgotinib is efficacious and safe in PsA

Data from the phase 2 study (EQUATOR-trial) shows that filgotinib is efficacious and safe in patients with psoriatic arthritis (PsA) [1]. “The selected Janus kinase (JAK)1 inhibitor improves multiple domains of PsA. No new safety data were obtained. This drug will be explored further in future PsA trials,” concluded Prof. Philip Mease (Swedish Medical Center and University of Washington, Seattle, USA) [2]. Filgotinib is an oral, selective JAK1 inhibitor in development for the treatment of several inflammatory diseases [1]. Prof. Mease et al. aimed to evaluate the onset and maintenance of response to filgotinib vs placebo in the EQUATOR trial by evaluating patient-level response over time. “What we are doing with this analysis is looking in a novel way at treatment response,” he said. The primary objective was to evaluate the time to first response on patient-level and the individual duration of response, compared with placebo. The secondary objectives were...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 4 September, 201917 March, 2021